Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.79)
# 1,958
Out of 4,984 analysts
45
Total ratings
36.11%
Success rate
49.06%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.52 | +42.59% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.01 | +845.27% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $12.69 | +136.41% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.30 | +1,598.84% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.73 | +318.85% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $22.03 | +467.41% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.68 | +389.13% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.28 | +479.27% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.90 | - | 1 | Oct 1, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $203.12 | -61.02% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $52.38 | +195.91% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.00 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.71 | +224.25% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.93 | +61,438.46% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.02 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.90 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.03 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $5.06 | +29,544.27% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.77 | +50,747.46% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.39 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.80 | +1,189.06% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $64.85 | +246.95% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.40 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.35 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.52
Upside: +42.59%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.01
Upside: +845.27%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $12.69
Upside: +136.41%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.30
Upside: +1,598.84%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.73
Upside: +318.85%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $22.03
Upside: +467.41%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.68
Upside: +389.13%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.28
Upside: +479.27%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.90
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $203.12
Upside: -61.02%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $52.38
Upside: +195.91%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $9.00
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $7.71
Upside: +224.25%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.93
Upside: +61,438.46%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $30.02
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.90
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.03
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $5.06
Upside: +29,544.27%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.77
Upside: +50,747.46%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.39
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.80
Upside: +1,189.06%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $64.85
Upside: +246.95%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.40
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.35
Upside: -